최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기Journal of medicinal chemistry, v.54 no.20, 2011년, pp.7066 - 7083
Guagnano, Vito , Furet, Pascal , Spanka, Carsten , Bordas, Vincent , Le Douget, Mickaël , Stamm, Christelle , Brueggen, Josef , Jensen, Michael R. , Schnell, Christian , Schmid, Herbert , Wartmann, Markus , Berghausen, Joerg , Drueckes, Peter , Zimmerlin, Alfred , Bussiere, Dirksen , Murray, Jeremy , Graus Porta, Diana
A novel series of N-aryl-N′-pyrimidin-4-yl ureas has been optimized to afford potent and selective inhibitors of the fibroblast growth factor receptor tyrosine kinases 1, 2, and 3 by rationally designing the substitution pattern of the aryl ring. On the basis of its in vitro profile, compound ...
Nature Rev. Drug Discovery Beenken A. 235 8 2009 10.1038/nrd2792
Nature Rev. Cancer Turner N. 116 10 2010 10.1038/nrc2780
Leukemia Walz C. 1005 19 2005 10.1038/sj.leu.2403712
Genes, Chromosomes Cancer Belloni E. 320 42 2005 10.1002/gcc.20144
Cancer Cell Roumiantsev S. 287 5 2004 10.1016/S1535-6108(04)00053-4
Genes, Chromosomes Cancer Grand E. K. 78 40 2004 10.1002/gcc.20023
Genes, Chromosomes Cancer Sohal J. 155 32 2001 10.1002/gcc.1177
Proc. Natl. Acad. Sci. U.S.A. Popovici C. 5712 95 1998 10.1073/pnas.95.10.5712
Regenass, U; Caravatti, G.; Fredenhagen, A.; Wacker, O.Patent WO9532975, 1995.
Proc. Natl. Acad. Sci. U.S.A. Chen J. 14479 101 2004 10.1073/pnas.0404438101
Cancer Res. Yagasaki F. 8371 61 2001
Nature Genet. Chesi M. 260 16 1997 10.1038/ng0797-260
Blood Richelda R. 4062 90 1997 10.1182/blood.V90.10.4062
Br. J. Hamaetol. Intini D. 362 114 2001 10.1046/j.1365-2141.2001.02957.x
Nature Genet. Cappellen D. 18 23 1999 10.1038/12615
Am. J. Pathol. Billerey C. 1955 158 2001 10.1016/S0002-9440(10)64665-2
Clin. Cancer Res. Gomez-Roman J. J. 459 11 2005 10.1158/1078-0432.459.11.2
Cancer Res. Jang J. H. 3541 61 2001
Clin. Cancer Res. Takeda M. 3051 13 2007 10.1158/1078-0432.CCR-06-2743
Cancer Res. Kunii K. 2340 68 2008 10.1158/0008-5472.CAN-07-5229
Oncogene Pollock P. M. 7158 26 2007 10.1038/sj.onc.1210529
Sci. Transl. Med. Weiss J. M. 62 2 2010 10.1126/scitranslmed.3001451
Clin. Cancer Res. Reis-Filho J. S. 6652 12 2006 10.1158/1078-0432.CCR-06-1164
Int. J. Cancer Penault-Llorca F. 170 61 1995 10.1002/ijc.2910610205
Int. J. Cancer Jacquemier J. 373 59 1994 10.1002/ijc.2910590314
Int. J. Cancer Jaakkola S. 378 54 1993 10.1002/ijc.2910540305
Genes, Chromosomes Cancer Theillet C. 219 7 1993 10.1002/gcc.2870070407
Oncogene Adnane J. 659 6 1991
Breast Cancer Res. Elsheikh S. E. R23 9 2007 10.1186/bcr1665
Cancer Genet. Cytogenet. Valladares A. 147 170 2006 10.1016/j.cancergencyto.2006.06.002
Int. J. Cancer Fioravanti L. 620 74 1997 10.1002/(SICI)1097-0215(19971219)74:6<620::AID-IJC11>3.0.CO;2-9
Oncogene Hui R. 1617 15 1997 10.1038/sj.onc.1201311
Gene Berns E. M. J. J. 11 159 1995 10.1016/0378-1119(94)00534-Y
Am. J. Clin. Pathol. Mayr D. 101 126 2006 10.1309/N6X5MB24BP42KP20
Int. J. Oncol. Seki A. 103 17 2000
J. Laryngol. Otol. Rubin J. S. 72 109 1995 10.1017/S0022215100129305
Cancer Lett. Hu L. 36 252 2007 10.1016/j.canlet.2006.12.003
Genomics Tsou A. P. 331 50 1998 10.1006/geno.1998.5338
J. Med. Chem. Gerald J. 4466 52 2009 10.1021/jm900431g
J. Med. Chem. Renhowe P. A. 278 52 2009 10.1021/jm800790t
J. Med. Chem. Bhide R. S. 2143 49 2006 10.1021/jm051106d
Hennequin, L. F. A.; Ple, P.; Stokes, E. S. E.; Mckerrecher, D.Quinazoline derivatives as angiogenesis inhibitors. Patent WO2000047212, 2000.
Cancer Res. Wedge S. R.; K. J. 4389 65 2005 10.1158/0008-5472.CAN-04-4409
Moussy, A.; Kinet, J.P.Use of dual C-KIT/FGFR3 inhibitors for treating multiple myeloma. Patent WO2007026251, 2007.
J. Med. Chem. Sun L. 5120 42 1999 10.1021/jm9904295
J. Med. Chem. Huang W.-S. 4701 53 2010 10.1021/jm100395q
Funahashi, Y.; Tsuruoka, A.; Matsukura, M.; Haneda, T.; Fukuda, Y.; Kamata, J.; Takahashi, K.; Matsushima, T.; Miyazaki, K.; Nomoto, K.; Watanabe, T.; Obaishi, H.; Yamaguchi, A.; Suzuki, S.; Nakamura, K.; Mimura, F.; Yamamoto, Y.; Matsui, J.; Matsui, K.; Yoshiba, T.; Suzuki, Y.; Arimoto, I.Nitrogenous aromatic ring compounds. Patent WO2002032872, 2002.
Int. J. Cancer Matsui J. 664 122 2007 10.1002/ijc.23131
10.1158/1538-7445.AM2011-3568 During the preparation of this manuscript, AstraZeneca disclosed the FGFR inhibitor AZD4547.Gavine, P. R.; Mooney, L.; Kilgour, E.; Thomas, A. P.; Al-Kadhimi, K.; Beck, S.; Coleman, T.; Baker, D.; Mellor, M. J.; Brooks, A. N.; Klinowska, T.Characterization of AZD4547: An orally bioavailable, potent and selective inhibitor of FGFR tyrosine kinases 1, 2 and 3.American Association for Cancer Research (AACR) 102nd Annual Meeting,Orlando, FL,April 2-6, 2011,Abstract 3568.
Bioorg. Med. Chem. Lett. Furet P. 897 18 2008 10.1016/j.bmcl.2007.12.041
J. Med. Chem. Thompson A. M. 4628 48 2005 10.1021/jm0500931
EMBO J. Mohammadi M. 5896 17 1998 10.1093/emboj/17.20.5896
Mol. Cell. Biol. Ong S. H. 979 20 2000 10.1128/MCB.20.3.979-989.2000
J. Comput. Chem. Mohamadi F. 440 11 1990 10.1002/jcc.540110405
Nucleic Acids Res. Bairoch A. 3578 22 1994 10.1093/nar/22.17.3626
J. Mol. Biol. Notredame C. 205 302 2000 10.1006/jmbi.2000.4042
J. Mol. Graphics Vriend G. 52 8 1990 10.1016/0263-7855(90)80070-V
Acta Crystallogr, Sect. D: Biol. Crystallogr. Bailey S. 760 50 1994 10.1107/S0907444993011898
Bricogne, G.; Blanc, E.; Brandl, M.; Flensburg, C.; Keller, P.; Paciorek, P.; Roversi, P.; Sharff, A.; Smart, O.; Vonrhein, C.; Woman, T.Buster 2.9;Global Phasing Ltd.:Cambridge, UK 2010.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.